Arthritis & Rheumatology
Published online: 6 February 2018
DOI: 10.1002/art.40397
Michael D. Richter MD, Olga Pinkston MD, Lisa A. Kottschade APRN, CNP, Heidi D. Finnes PharmD, Svetomir N. Markovic MD, PhD, Uma Thanarajasingam MD, PhD
Objectives: To determine the risk of rheumatic disease flare and adverse effects in patients with preexisting rheumatic disease who were receiving immune checkpoint inhibitor (ICI) therapy.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.